Clinical survey on contrast-induced nephropathy after coronary angiography

Figures & data

Table 1. Comparison of incidences of CIN through risk score stratification.

Risk scores	None-CIN (n, %)	CIN (n, %)	Total
All cases
≤5	130, 96.3%	5, 3.7%	135
6–10	170, 88.5%	22, 11.5%	192
11–15	95, 86.4%	15, 13.6%	110
≥16	41, 82.0%	9, 18.0%	50
Total (n, %)	436, 89.5%	51, 10.5%	487
Low-risk	121, 96.0%	5, 4.0%	126
High-risk	315, 87.3%	46, 12.7%	361
Total (n, %)	436, 89.5%	51, 10.5%	487
Excluding postoperative heart failure
≤5	130, 97.0%	4, 3.0%	134
6–10	169, 91.8%	15, 8.2%	184
11–15	93, 89.4%	11, 10.6%	104
≥16	39, 88.6%	5, 11.4%	44
Total (n, %)	431, 92.5%	35, 7.5%	466
Low-risk	121, 96.8%	4, 3.2%	125
Low-risk	310, 90.9%	31, 9.1%	341
Total (n, %)	431, 92.5%	35, 7.5%	466

Notes: Group CIN, patients with CIN. Group non-CIN, patients without CIN.

Table 2. Comparison of clinical parameters between CIN group and non-CIN group.

	Non-CIN	CIN	T	Z	p
Hb, g/L	132.6 ± 18.6	124.6 ± 22.8	2.383	/	0.021*
Hct, %	38.7 ± 4.8	36.28 ± 6.5	2.482	/	0.016*
SCr, µmol/L	92.4 ± 36.4	99.8 ± 57.0	−0.913	/	0.365
TC, mmol/L	4.5 ± 1.2	4.6 ± 1.3	−0.576	/	0.565
LDL, mmol/L	3.0 ± 1.1	3.37 ± 1.1	−1.966	/	0.050
P, mmol/L	1.1 ± 0.2	1.0 ± 0.3	0.624	/	0.533
Ca^2+, mmol/L	2.3 ± 1.5	2.2 ± 0.4	0.892	/	0.373
eGFR, mL/min ċ 1.73 m^2	71.5 ± 29.3	71.90 ± 40.9	−0.062	/	0.951
LVMI	97.3 ± 28.6	101.7 ± 31.8	−0.872	/	0.384
Length of hospital stay	/	/	/	−3.566	0.000*
Heart failure	/	/	/	−4.852	0.000*
GA, %	/	/	/	−2.907	0.004*
DD, µg/L	/	/	/	−3.330	0.001*
BNP, pmol/mL	/	/	/	−4.358	0.000*
CRP, mg/L	/	/	/	−2.171	0.030*
AST, U/L	/	/	/	−2.603	0.009*
CPK, U/L	/	/	/	−2.650	0.008*
LDH, U/L	/	/	/	−3.603	0.000*
EF, %	/	/	/	−3.357	0.001*
cTnI, u/L	/	/	/	−3.048	0.002*
CKMB, U/L	/	/	/	−2.747	0.006*

Notes: Hb, hemoglobin; Hct, hematocrit; SCr, serum creatinine; TC, total cholesterol; LDL, low density lipoprotein; P, phosphorus; Ca²+, serum calcium; eGFR, estimated glomerular filtration rate; LVMI, left ventricular mass index; GA, glycated albumin; DD, D-dimer; BNP, brain natriuretic peptide; CRP, C reactive protein; AST, aspartate aminotransferase; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; EF, ejection fraction; cTnI, cardiac troponin I; CKMB, creatine phosphokinase MB; Group CIN, patients with CIN; Group non-CIN, patients without CIN.

*p < 0.05 versus non-CIN.

Table 3. Chi-square test results of the incidence of CIN by risk factors.

	OR	p
All cases
Age ≥75 years	N/A	0.442
Preoperative hypotension	3.870	0.004
IABP	8.857	0.056
Heart failure	3.599	0.000
Anemia	3.483	0.000
Diabetes	N/A	0.574
eGFR ≤ 30 ml/min	2.046	0.043
Excluding postoperative heart failure
Age ≥75 years	N/A	0.203
Preoperative hypotension	N/A	1.000
IABP	N/A	1.000
Heart failure	5.365	0.000
Anemia	2.818	0.063
Diabetes	N/A	0.988
eGFR ≤ 30 ml/min	3.843	0.049

Notes: IABP, intraaortic bloon pump; eGFR, estimated glomerular filtration rate.

Figure 1. Comparison of the incidence of CIN with different contrast media. Group CIN, patients with CIN. Group non-CIN, patients without CIN. *p > 0.05 versus non-CIN.

Table 4. Logistic regression analysis of CIN incidence-related factors.

Variable	p	OR
Male	0.047	2.999
Weight	0.001	0.905
Emergency PCI	0.014	3.158
Heart failure	0.004	1.809
Hb	0.003	0.961
ALB	0.002	1.195
BUN	0.004	1.052
Diuretics	0.023	3.196
eGFR	0.000	1.039

Notes: Hb, hemoglobin; ALB, albumin; BUN, blood nitrogen urea; eGFR, estimated glomerular filtration rate.

Figure 2. Prognosis of patients in CIN and non-CIN groups. (A) Death rate of CIN patients in hospital. (B) Death rate of CIN patients during follow-up time. Group CIN, patients with CIN. Group non-CIN, patients without CIN. *p > 0.05 versus non-CIN.